(RTTNews) - Revvity, Inc. (RVTY) announced a strategic collaboration with Profluent, resulting in a simplified access for customers to a therapeutically relevant base editing toolkit. The new Pin-point configuration allows for increased precision and efficiency, with some combinations being precise to single nucleotide edits without bystander editing.
The company said the combination of the Pin-point platform and a curated selection of Profluent's adenine deaminases are available from Revvity through bundled licensing to significantly expand the number of disease-related mutations that could be addressed using the Pin-point platform and accelerate adoption by therapeutic developers.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
